# NKGen Biotech Inc. (NKGN)

Source: https://www.quantisnow.com/company/NKGN
Generated: 2026-11-22T16:23:52.291Z

- Ticker: NKGN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)

## Latest NKGN news and filings

- 2026-11-16 18:05 UTC [NKGen Biotech Reports Long-Term Clinical Observations with Investigational Alzheimer’s Treatment Troculeucel at CTAD 2026](https://www.quantisnow.com/insight/nkgen-biotech-reports-long-term-clinical-observations-with-investigational-alzheimers-treatment-6793574)
- 2026-11-09 13:05 UTC [NKGen Biotech to Present Long-Term Follow-Up of Troculeucel in Moderate Alzheimer’s Disease at CTAD 2026](https://www.quantisnow.com/insight/nkgen-biotech-to-present-long-term-follow-up-of-troculeucel-in-moderate-6780418)
- 2026-09-15 12:05 UTC [NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum](https://www.quantisnow.com/insight/nkgen-biotech-to-present-on-troculeucel-for-neurodegenerative-diseases-at-6715475)
- 2026-09-10 12:05 UTC [NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026](https://www.quantisnow.com/insight/nkgen-biotech-to-present-on-potential-of-troculeucel-in-neurodegenerative-6710927)
- 2026-07-02 12:05 UTC [Conference Announcement] [NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions](https://www.quantisnow.com/insight/nkgen-biotech-to-present-at-the-2026-biochina-global-forum-6624279)
- 2026-06-02 13:02 UTC [A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company](https://www.quantisnow.com/insight/a-third-cancer-drug-just-entered-the-clinic-at-an-6583554)
- 2026-05-19 12:05 UTC [NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment](https://www.quantisnow.com/insight/nkgen-biotech-expands-clinical-trial-site-network-for-alzheimers-disease-6561752)
- 2026-04-09 12:05 UTC [NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit](https://www.quantisnow.com/insight/nkgen-biotech-to-present-troculeucel-mechanism-data-in-alzheimers-and-6493966)
- 2026-03-23 12:05 UTC [NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™](https://www.quantisnow.com/insight/nkgen-biotech-reports-combined-phase-1-troculeucel-data-demonstrating-dose-responsive-6464331)
- 2026-03-10 12:05 UTC [NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026](https://www.quantisnow.com/insight/nkgen-biotech-to-present-integrated-phase-1-clinical-and-biomarker-6438748)
- 2026-01-22 13:05 UTC [Leadership Update] [NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board](https://www.quantisnow.com/insight/nkgen-biotech-names-leading-dementia-expert-bruce-l-miller-md-6357137)
- 2026-01-20 12:07 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by NKGen Biotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-nkgen-biotech-inc-6353186)
- 2026-01-16 22:25 UTC [SEC Form 8-K] [NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nkgen-biotech-inc-filed-sec-form-8-k-entry-into-a-6352612)
- 2026-01-09 22:25 UTC [SEC Form 8-K] [NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nkgen-biotech-inc-filed-sec-form-8-k-entry-into-a-6344817)
- 2025-12-03 13:05 UTC [Leadership Update] [NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.](https://www.quantisnow.com/insight/nkgen-biotech-inc-issues-statement-on-recent-board-appointments-at-6300804)
- 2025-10-09 12:05 UTC [NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market](https://www.quantisnow.com/insight/nkgen-biotech-provides-clarification-on-quotation-display-and-trading-status-6228376)
- 2025-10-06 12:05 UTC [NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology](https://www.quantisnow.com/insight/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-6223953)
- 2025-09-18 12:05 UTC [NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum](https://www.quantisnow.com/insight/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-6205046)
- 2025-09-09 12:05 UTC [Mergers & Acquisitions] [NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets](https://www.quantisnow.com/insight/nkgen-biotech-inc-announces-completion-of-nkmax-co-ltd-acquisition-6194388)
- 2025-08-06 12:00 UTC [NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit](https://www.quantisnow.com/insight/nkgen-biotech-to-present-on-allogeneic-enhanced-nk-cells-without-6149244)
- 2025-07-28 12:05 UTC [NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025](https://www.quantisnow.com/insight/nkgen-biotech-presents-troculeucel-mechanism-of-action-with-corresponding-phase-6133757)
- 2025-07-22 12:05 UTC [Conference Announcement] [NKGen Biotech to Present at the Alzheimer's Association International Conference 2025](https://www.quantisnow.com/insight/nkgen-biotech-to-present-at-the-alzheimers-association-international-conference-6127698)
- 2025-07-21 12:00 UTC [NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases](https://www.quantisnow.com/insight/nkgen-receives-fda-expanded-access-protocol-authorization-for-landmark-treatment-6126202)
- 2025-07-17 20:33 UTC [SEC Form 8-K] [NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nkgen-biotech-inc-filed-sec-form-8-k-entry-into-a-6124031)
- 2025-07-17 20:05 UTC [NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan](https://www.quantisnow.com/insight/nkgen-biotech-and-hekabio-enter-strategic-partnership-to-bring-novel-6123689)
- 2025-07-17 17:25 UTC [SEC Form 25-NSE filed by NKGen Biotech Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-nkgen-biotech-inc-6123531)
- 2025-07-16 21:45 UTC [NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards](https://www.quantisnow.com/insight/nkgen-biotech-announces-new-funding-to-regain-compliance-with-reporting-6122565)
- 2025-07-16 21:25 UTC [SEC Form 8-K] [NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nkgen-biotech-inc-filed-sec-form-8-k-entry-into-a-6122525)
- 2025-07-10 20:30 UTC [NKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy](https://www.quantisnow.com/insight/nkgen-biotech-administers-first-dose-of-troculeucel-to-alzheimers-patient-6116979)
- 2025-06-23 12:05 UTC [NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and Florida](https://www.quantisnow.com/insight/nkgen-biotech-announces-international-and-us-expansion-of-phase-12a-6094940)
- 2025-06-20 12:00 UTC [SEC Form 8-K] [NKGen Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nkgen-biotech-inc-filed-sec-form-8-k-other-events-financial-6093094)
- 2025-06-02 16:11 UTC [Insider Buy] [Large owner Cfic-2015 Nv Family Investments, Llc bought $2,500,000 worth of shares (19,669,552 units at $0.13), increasing direct ownership by 944% to 21,752,885 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-cfic-2015-nv-family-investments-llc-bought-2500000-worth-6067078)
- 2025-05-20 12:00 UTC [SEC Form 8-K] [NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nkgen-biotech-inc-filed-sec-form-8-k-entry-into-a-6049471)
- 2025-05-15 20:05 UTC [SEC Form NT 10-Q filed by NKGen Biotech Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-nkgen-biotech-inc-6042062)
- 2025-05-12 20:15 UTC [SEC Form SCHEDULE 13D filed by NKGen Biotech Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-nkgen-biotech-inc-6033222)
- 2025-05-08 12:06 UTC [SEC Form 8-K] [NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nkgen-biotech-inc-filed-sec-form-8-k-entry-into-a-6026181)
- 2025-05-08 12:05 UTC [NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations](https://www.quantisnow.com/insight/nkgen-biotech-chairman-ceo-paul-y-song-md-personally-invests-6026165)
- 2025-05-07 20:05 UTC [Insider Buy] [Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-song-paul-y-bought-2650000-worth-of-6023915)
- 2025-05-07 12:00 UTC [NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting](https://www.quantisnow.com/insight/nkgen-biotech-to-present-troculeucel-clinical-and-biomarker-results-at-6022752)
- 2025-05-01 20:05 UTC [SEC Form 8-K] [NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nkgen-biotech-inc-filed-sec-form-8-k-entry-into-a-6013290)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NKGN
- Earnings history: https://www.quantisnow.com/earnings/NKGN
- Dividend history: https://www.quantisnow.com/dividends/NKGN
- Insider transactions: https://www.quantisnow.com/insiders/NKGN
- Options chain: https://www.quantisnow.com/options/NKGN
- SEC 8-K filings only: https://www.quantisnow.com/company/NKGN/8-k
- RSS and alerts for NKGN: https://www.quantisnow.com/docs/rss-feeds.md
